We are pleased to announce that WuXi NextCODE have partnered up with The San Antonio 1000 Cancer Genomes Project (SA1kCGP) and South Texas Accelerated Research Therapeutics (START) to speed a pioneering city-based population cancer genomics effort, aimed at contributing directly to improving the clinical treatment of cancer around the world. The SA1kCGP brings together hundreds of doctors, oncologists and surgeons, and a thousand patients to create a unique resource of tumor and germline data from breast, lung, prostate, skin, colorectal, uterine, pancreatic, ovarian, stomach and brain cancers, collected at the time of diagnosis. START, which operates the world’s largest Phase I medical oncology program through clinical sites in the U.S., China and Spain, will use WuXi NextCODE’s capabilities to sequence and interpret the samples.
San Antonio is innovating locally and impacting globally. We’re thrilled to be part of this mission to create better medicine for patients everywhere and speed the delivery of the latest in genome-driven therapy straight to cancer patients.